N/A N=74 CONtrolled Focal Fibrous Band Release Method Study
Cellulite
Primary: The Mean Change From Baseline to 3 Months in Cellulite Severity Scale (CSS) Score for Participants — 1.5 score on a scale — p=.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Evaluation of Hearing Aid Benefit
Hearing Loss, Sensorineural
Primary: Speech Intelligibility in Quiet. — 92.3; 90.6 percentage of correct responses
N/A N=500 Preventing Depressive Relapse in Pregnant Women With Recurrent Depression
Depression · Pregnancy Related · Antenatal Depression
Primary: Number of Participants Experiencing Relapse of Depression — 81; 111 Participants
Phase 2 N=71 LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in Chronic Sinusitis Symptom Scores at Week 4 — -2.24; -2.65; -2.28 score on a scale
N/A N=35 Evaluation of Multifocal Contact Lens Designs With and Without an HEV Blocker on Visual Function
Visual Acuity
Primary: Starburst Diameter (mm) — 77.06; 64.13; 67.26; 54.24 mm
N/A N=73 Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week of Wear
Ocular Physiology
Primary: Proportion of Eyes With Grade 3 or Higher Slit Lamp Findings — 0; 0 Proportion of eyes
Phase 2 N=149 Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain
Lumbosacral Radiculopathy
Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale…
Phase 2 N=200 A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 4.0; 29.3; 4.0; 43.3 percentage of participants
N/A N=2,778 You and Me COVID Free
COVID-19
Primary: Main Reason for Testing for COVID-19 — 1632; 493; 238; 343 Participants
Phase 4 N=32 Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Diabetes Mellitus, Type 2
Primary: Endogenous Glucose Production Measurement — 155; 121; 104; 98 mg/dl
Phase 2 N=56 Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
Anemia · Myelodysplastic/Myeloproliferative Neoplasm · Myelofibrosis
Primary: Anemia-response — 8; 6 Participants
Phase 2 N=50 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · Primary Myelofibrosis · Secondary Myelofibrosis
Primary: Number of Participants With a Response — 15 Participants
N/A N=51 Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy
Cicatrix · Carbon Dioxide Laser
Primary: Change in Vectra Measured Length V1 (Month 0)-V2 (Month 3) for Original Group; Visit 3 (Month 6) to Visit 4 (Month 9) for Crossover Group — 0.10; 0.03 mm
N/A N=300 Single Dose Monurol for Treatment of Acute Cystitis
Urinary Tract Infection
Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001
N/A N=101 BRITEPath- Phase 2
Depression · Suicidal Ideation
Primary: Depression Severity — 8.6; 10.8 score on a scale